Browsing by Author "Jacobs, Chelsea C."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study
    (Elsevier, 2023) Ichkhanian, Yervant; Al-Haddad, Mohammad A.; Jacobs, Chelsea C.; Schlachterman, Alexander; Yang, Juliana; Canakis, Andrew; Kim, Raymond; Guerson-Gil, Arcelia; D'Souza, Lionel S.; Alsheik, Eva; Ginnebaugh, Brian D.; Khashab, Mouen A.; Zuchelli, Tobias; McFarlin, Kellie; Piraka, Cyrus; Medicine, School of Medicine
    Background and Aims Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation. Methods This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM. Results A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls. Conclusions Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS. Abbreviations:
  • Thumbnail Image
    Item
    Per-Oral Endoscopic Myotomy for Esophagogastric Junction Outflow Obstruction: A Multicenter Pilot Study
    (Elsevier, 2020) Jacobs, Chelsea C.; Perbtani, Yaseen; Yang, Dennis; Al-Haddad, Mohammad A.; Obaitan, Ite; Othman, Mohamed; Groth, Shawn; Sethi, Amrita; Agarunov, Emil; Repici, Alessandro; Maselli, Roberta; Galtieri, Alessia; Moremen, Jacob; Jenkins, Haley N.; Samarasena, Jason B.; Chang, Kenneth J.; Draganov, Peter V.; Medicine, School of Medicine
  • Thumbnail Image
    Item
    Prevalence and Impact of Opioid Use in Patients Undergoing Peroral Endoscopic Myotomy
    (Elsevier, 2023-04) Jacobs, Chelsea C.; Al-Haddad, Mohammad; Stainko, Sarah; Perkins, Anthony; DeWitt, John M.; Medicine, School of Medicine
    Background and Aims Chronic narcotic use may cause opioid-induced esophageal dysfunction (OIED) and associated type 3 achalasia, hypercontractile esophagus (HE), diffuse esophageal spasm (DES) and esophagogastric junction outflow obstruction (EGJOO). The frequency of opioid use and its impact on peroral endoscopic myotomy (POEM) in these patients is unknown. Methods Consecutive patients between 04/2017 and 09/2021 who underwent POEM for type III achalasia, EGJOO, DES, or HE with ≥6 months follow-up were identified. Baseline evaluation: EGD, high resolution esophageal manometry (HRM) and functional lumen impedance planimetry (FLIP) of the esophagogastric junction (EGJ). Eckardt scores (ES) were calculated at baseline and follow-up at 6-12 months post-POEM for opioid users and opioid non-users. Clinical response (CR) was defined as ES≤3, EGJ-distensibility index (DI)>2.8mm2/mmHg, maximum EGJ diameter (MxEGJD)>14mm and integrated relaxation pressure (IRP)<15mmHg. Opioid use prior to baseline HRM was assessed. Results 126 patients underwent POEM and 89 had ≥6 months follow-up. Daily opioid use was present in 18/89 (20%). Baseline demographics, FLIP metrics, IRP, distribution of motility disorders and POEM characteristics were similar between both groups. At 6-12 months after POEM, clinical response as well as frequency of GERD, esophagitis, and PPI use were similar between opioid users and non-users. Heartburn was more frequent in the opioid group (82.4% vs 38.6%, p=0.002). Conclusion In this single center study of 89 patients with type III achalasia, EGJOO, DES, or HE treated with POEM, daily opioid use was present in 20%. Response to POEM and post-POEM GERD were similar between opioid and non-opioid users.